- Kinase inhibitors - important first-in-class drug
- Numerous ‘me-too’ drugs in development for type II diabetes
- Metabolic disorders, oncology and central nervous system disorders attract the highest number of molecules at late stage development
LONDON--(BUSINESS WIRE)-- Metabolic disorders, oncology and central nervous system disorders attract the highest number of molecules at late stage development, according to a new report available on companiesandmarkets.com. Of these, oncology drugs represent 37% of total product pipeline activity, as there is a strong unmet need for effective, well tolerated cancer treatments.
Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development
There are a number of companies which are conducting R&D on protein-based therapies for oncology conditions, including Amgen, Bristol-Myers Squibb, Pfizer and Sanofi-aventis. Protein therapies have been seen to induce fewer debilitating side-effects when compared with existing chemotherapy treatments.
Tyrosine kinase inhibitors are the most common type of drugs undergoing Phase II and III trials, with around 40% of all Phase III oncology trials involving molecules of this nature. Kinase inhibitors are also being developed for treatment of diabetes, autoimmune diseases and restenosis, amongst others.
Vaccines, mTOR inhibitors and Cytochrome P450 inhibitors also have a strong present in the late stage development pipeline.
The drug discovery pipeline includes 174 ‘me too’ therapies to treat type II diabetes, which have the same or similar action as existing drugs. These drugs sometimes offer additional benefits, such as improved safety and efficacy. Examples of these include glucagon-like peptide-1 (GLP-1) analogues and glitazones.
The 132 page late stage drug pipeline research report was published in July 2011, and provides a comprehensive review and analysis of late stage pipeline molecules for several conditions. The report also compares drugs in development for major indications by therapy area, phase, unmet need, safety, efficacy, mechanism of action, stage of target disease and technology trends. Drugs with blockbuster potential are identified, and forecast sales of oncology treatment drugs to 2017 are also provided.
Companies & Markets
London (UK): +44 (0) 203 086 8600
KEYWORDS: United Kingdom Europe
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Communications Marketing